Anebulo Pharmaceuticals (NASDAQ:ANEB) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Anebulo Pharmaceuticals (NASDAQ:ANEB) announced its quarterly earnings data on Wednesday. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.08, Yahoo Finance reports.

Anebulo Pharmaceuticals Stock Performance

Shares of ANEB opened at $2.05 on Friday. The firm has a market cap of $53.16 million, a PE ratio of -5.54 and a beta of -1.01. Anebulo Pharmaceuticals has a 52-week low of $1.62 and a 52-week high of $3.61. The business’s 50 day moving average price is $2.05 and its two-hundred day moving average price is $2.35.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.